Creating Impact Together
Progress is built on collective contributions.
Ichnos Sciences welcomes collaboration with partners that have bold ideas and capabilities that complement and stretch our potential to shift progress, advance science, and deliver transformative medicines.
Oncology Pipeline and the BEAT® Platform Partnerships
Ichnos is committed to advancing our clinical-stage oncology portfolio and the next wave of discovery-stage assets. We are looking for partners who are interested in collaborating with us as we work to bring multispecific antibodies to patients with hematologic cancers and solid tumors.
- Heavy chain pairing technology
- Heavy/light chain pairing technology using a common light chain
- Proprietary tools for selection of high-quality antibodies (phage and mammalian display)
- Effective target affinity maturation
- Efficient purification aided by differential binding to Protein A, 95% yield in a single purification step
- Flexible platform enables exploration of the full design space
- Fc function activity can be modulated (T-cell: silent; non T-cell: active – enhanced)
- Comprehensive screening capabilities enabling fast identification of leads with best functional activity and drug-like properties
Interested in partnering? Connect with us at our Contact Us page
Autoimmune Disease Partnerships
Ichnos is out-licensing two assets that were developed to treat a range of autoimmune diseases with high unmet need.
| Asset / MOA | Status | Licensee |
|---|---|---|
|
|
|
|
|
|
View Career Opportunities
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.
